stockrow
Friday 6 November 2026
Export TGTX’s income statement to Excel — free account
TG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
59.37
1.39
+2.40%
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) revenue by segment, product and region
Where the money comes from and where it goes
| Product | 314 | 95.36% |
|---|---|---|
| Milestone | 13 | 3.80% |
| Other Revenue | 2 | 0.55% |
| Royalty | 1 | 0.24% |
| License Revenue | 0 | 0.05% |
| Gross margin | 88.30% | |
| Operating margin | 12.74% | |
| Pre-tax margin | 7.78% |
Revenue by product or service $m
| Line | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Product | 607 98.48% | 314 95.36% | 92 39.38% | — | — |
| Royalty | 6 0.91% | 1 0.24% | 0 0.00% | — | — |
| Other Revenue | 4 0.58% | 2 0.55% | 2 0.64% | — | — |
| License Revenue | 0 0.02% | 0 0.05% | 140 59.98% | — | — |
| Milestone | 0 0.00% | 13 3.80% | 0 0.00% | — | — |
| License | 9 | 15 | 142 | — | — |
| Revenue | 616 | 329 | 234 | 0 | 0 |